How severe is CVE-2019-13157?

CVE-2019-13157 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity high, and availability none.

Is CVE-2019-13157 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (75th percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2019-13157?

CVE-2019-13157 affects Naver Vaccine. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2019-13157?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

When was CVE-2019-13157 published?

CVE-2019-13157 was published on 2019-11-22 and last updated on 2026-06-17.

CVE-2019-13157

CVE-2019-13157 is a high-severity vulnerability in Naver Vaccine with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-22.

Key facts

Severity: High (CVSS 3.x base score 7.5)
CVSS v2: 6.4
EPSS exploit prediction: 2% (75th percentile)
Actively exploited: Not listed in CISA KEV
Weakness: CWE-22
Affected product: Naver Vaccine
Published: 2019-11-22
Last modified: 2026-06-17

Description

nsGreen.dll in Naver Vaccine 2.1.4 allows remote attackers to overwrite arbitary files via directory traversal sequences in a filename within nsz archive.

Frequently asked questions

What is CVE-2019-13157?: nsGreen.dll in Naver Vaccine 2.1.4 allows remote attackers to overwrite arbitary files via directory traversal sequences in a filename within nsz archive.
How severe is CVE-2019-13157?: CVE-2019-13157 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity high, and availability none.
Is CVE-2019-13157 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 2% (75th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2019-13157?: CVE-2019-13157 affects Naver Vaccine. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2019-13157?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2019-13157 published?: CVE-2019-13157 was published on 2019-11-22 and last updated on 2026-06-17.

References

https://cve.naver.com/detail/cve-2019-13157

Affected products (1)

cpe:2.3:a:naver:vaccine:2.1.4:*:*:*:*:*:*:*

Other CWE-22 (Path Traversal) vulnerabilities

CVE-2026-76606 — Critical (CVSS 10.0): Joomla Extension - fabrikar.com - Path Traversal via image element in Fabrik < 4.7.3 - ???.
CVE-2026-18051 — Critical (CVSS 10.0): The W3 Total Cache WordPress plugin before 2.10.5 does not properly validate the request path it uses to build cache…
CVE-2026-74764 — Critical (CVSS 10.0): Pandora contains a path traversal vulnerability in its TAR archive extraction functionality. When processing a…
CVE-2026-16940 — Critical (CVSS 10.0): The Custom Fields WordPress plugin before 1.5.1 does not validate a user-supplied file path before deletion, allowing…
CVE-2026-67429 — Critical (CVSS 10.0): Flyto2 Core is an execution kernel for automation and AI-agent workflows. Prior to 2.26.6, image.download and related…
CVE-2026-59555 — Critical (CVSS 10.0): Unauthenticated Arbitrary File Deletion in Participants Database <= 2.7.8.3 versions.

Browse all CWE-22 (Path Traversal) vulnerabilities →